AAPL338.30-6.34 (-1.84%) ▼|ABBV287.75-7.14 (-2.42%) ▼|ABT109.90+3.70 (+3.48%) ▲|ACN262.81+4.57 (+1.77%) ▲|ADBE255.00+4.77 (+1.91%) ▲|AMAT387.78-2.31 (-0.59%) ▼|AMD483.88-20.93 (-4.15%) ▼|AMGN466.59+0.58 (+0.12%) ▲|AMT188.18+0.40 (+0.21%) ▲|AMZN250.14+9.79 (+4.07%) ▲|AVGO329.94+3.86 (+1.18%) ▲|AXP328.87+9.76 (+3.06%) ▲|BA175.65+4.10 (+2.39%) ▲|BAC50.24+0.23 (+0.46%) ▲|BKNG155.04+6.91 (+4.66%) ▲|BLK1,174.62+27.08 (+2.36%) ▲|BMY62.46-0.02 (-0.03%) ▼|BNY148.30+1.19 (+0.81%) ▲|BRK-B554.76+12.27 (+2.26%) ▲|C123.82+1.85 (+1.52%) ▲|CAT623.25+0.50 (+0.08%) ▲|CL96.99+1.70 (+1.78%) ▲|CMCSA23.75+0.53 (+2.28%) ▲|COF212.07+7.22 (+3.52%) ▲|COP147.31-6.72 (-4.36%) ▼|COST1,039.22+26.94 (+2.66%) ▲|CRM232.27+3.10 (+1.35%) ▲|CSCO103.19-1.32 (-1.26%) ▼|CVS88.53-1.73 (-1.91%) ▼|CVX228.15-7.37 (-3.13%) ▼|DE664.40-11.08 (-1.64%) ▼|DHR229.50-2.73 (-1.18%) ▼|DIS113.60+2.66 (+2.40%) ▲|DUK127.93+0.54 (+0.42%) ▲|EMR168.41+3.47 (+2.10%) ▲|FDX319.72+6.44 (+2.06%) ▲|GD369.31-3.29 (-0.88%) ▼|GE315.95+14.15 (+4.69%) ▲|GEV877.20+19.33 (+2.25%) ▲|GILD170.19-0.49 (-0.29%) ▼|GM89.40+2.00 (+2.28%) ▲|GOOG281.97+3.75 (+1.35%) ▲|GOOGL283.48+3.64 (+1.30%) ▲|GS909.74+15.19 (+1.70%) ▲|HD339.46+10.26 (+3.12%) ▲|HON225.16+6.83 (+3.13%) ▲|IBM258.34+0.53 (+0.21%) ▲|INTC61.96-3.81 (-5.79%) ▼|INTU355.56+14.47 (+4.24%) ▲|ISRG444.94+12.93 (+2.99%) ▲|JNJ269.26-3.94 (-1.44%) ▼|JPM341.71+4.67 (+1.38%) ▲|KO95.69+1.61 (+1.71%) ▲|LIN521.96+7.72 (+1.50%) ▲|LLY1,412.61-4.93 (-0.35%) ▼|LMT641.11+4.16 (+0.65%) ▲|LOW216.26+7.19 (+3.44%) ▲|LRCX232.86-6.25 (-2.61%) ▼|MA659.63+21.62 (+3.39%) ▲|MCD263.87+5.75 (+2.23%) ▲|MDLZ66.05+1.11 (+1.70%) ▲|MDT98.69+2.15 (+2.23%) ▲|META612.09-2.90 (-0.47%) ▼|MMM179.35+5.01 (+2.87%) ▲|MO77.51-0.52 (-0.67%) ▼|MRK148.53-0.99 (-0.66%) ▼|MS186.52+2.22 (+1.20%) ▲|MSFT520.02-1.90 (-0.36%) ▼|MU852.74-32.00 (-3.62%) ▼|NEE84.99+1.28 (+1.52%) ▲|NFLX62.60+0.52 (+0.84%) ▲|NKE39.53+0.86 (+2.22%) ▲|NOW108.78+3.66 (+3.48%) ▲|NVDA206.58+1.94 (+0.95%) ▲|ORCL122.29-8.38 (-6.41%) ▼|PEP140.01+2.67 (+1.94%) ▲|PFE30.71+0.19 (+0.61%) ▲|PG163.79+2.22 (+1.37%) ▲|PLTR184.31+0.20 (+0.11%) ▲|PM208.04-0.75 (-0.36%) ▼|QCOM166.20+1.41 (+0.86%) ▲|RTX201.84+2.04 (+1.02%) ▲|SBUX103.86+0.21 (+0.20%) ▲|SCHW89.25+1.20 (+1.36%) ▲|SO94.31+0.60 (+0.64%) ▲|SPG222.83+5.08 (+2.33%) ▲|T21.44+0.03 (+0.14%) ▲|TMO685.44-11.56 (-1.66%) ▼|TMUS158.56+2.12 (+1.36%) ▲|TSLA408.55+8.74 (+2.18%) ▲|TXN308.30+7.46 (+2.48%) ▲|UBER67.19+1.94 (+2.97%) ▲|UNH397.41-9.57 (-2.35%) ▼|UNP307.49+3.49 (+1.15%) ▲|UPS109.57+1.32 (+1.22%) ▲|USB60.52+1.07 (+1.80%) ▲|V426.08+12.49 (+3.02%) ▲|VZ44.94+0.21 (+0.46%) ▲|WFC84.96+1.56 (+1.86%) ▲|WMT126.97+3.46 (+2.80%) ▲|XOM180.46-6.79 (-3.63%) ▼|AAPL338.30-6.34 (-1.84%) ▼|ABBV287.75-7.14 (-2.42%) ▼|ABT109.90+3.70 (+3.48%) ▲|ACN262.81+4.57 (+1.77%) ▲|ADBE255.00+4.77 (+1.91%) ▲|AMAT387.78-2.31 (-0.59%) ▼|AMD483.88-20.93 (-4.15%) ▼|AMGN466.59+0.58 (+0.12%) ▲|AMT188.18+0.40 (+0.21%) ▲|AMZN250.14+9.79 (+4.07%) ▲|AVGO329.94+3.86 (+1.18%) ▲|AXP328.87+9.76 (+3.06%) ▲|BA175.65+4.10 (+2.39%) ▲|BAC50.24+0.23 (+0.46%) ▲|BKNG155.04+6.91 (+4.66%) ▲|BLK1,174.62+27.08 (+2.36%) ▲|BMY62.46-0.02 (-0.03%) ▼|BNY148.30+1.19 (+0.81%) ▲|BRK-B554.76+12.27 (+2.26%) ▲|C123.82+1.85 (+1.52%) ▲|CAT623.25+0.50 (+0.08%) ▲|CL96.99+1.70 (+1.78%) ▲|CMCSA23.75+0.53 (+2.28%) ▲|COF212.07+7.22 (+3.52%) ▲|COP147.31-6.72 (-4.36%) ▼|COST1,039.22+26.94 (+2.66%) ▲|CRM232.27+3.10 (+1.35%) ▲|CSCO103.19-1.32 (-1.26%) ▼|CVS88.53-1.73 (-1.91%) ▼|CVX228.15-7.37 (-3.13%) ▼|DE664.40-11.08 (-1.64%) ▼|DHR229.50-2.73 (-1.18%) ▼|DIS113.60+2.66 (+2.40%) ▲|DUK127.93+0.54 (+0.42%) ▲|EMR168.41+3.47 (+2.10%) ▲|FDX319.72+6.44 (+2.06%) ▲|GD369.31-3.29 (-0.88%) ▼|GE315.95+14.15 (+4.69%) ▲|GEV877.20+19.33 (+2.25%) ▲|GILD170.19-0.49 (-0.29%) ▼|GM89.40+2.00 (+2.28%) ▲|GOOG281.97+3.75 (+1.35%) ▲|GOOGL283.48+3.64 (+1.30%) ▲|GS909.74+15.19 (+1.70%) ▲|HD339.46+10.26 (+3.12%) ▲|HON225.16+6.83 (+3.13%) ▲|IBM258.34+0.53 (+0.21%) ▲|INTC61.96-3.81 (-5.79%) ▼|INTU355.56+14.47 (+4.24%) ▲|ISRG444.94+12.93 (+2.99%) ▲|JNJ269.26-3.94 (-1.44%) ▼|JPM341.71+4.67 (+1.38%) ▲|KO95.69+1.61 (+1.71%) ▲|LIN521.96+7.72 (+1.50%) ▲|LLY1,412.61-4.93 (-0.35%) ▼|LMT641.11+4.16 (+0.65%) ▲|LOW216.26+7.19 (+3.44%) ▲|LRCX232.86-6.25 (-2.61%) ▼|MA659.63+21.62 (+3.39%) ▲|MCD263.87+5.75 (+2.23%) ▲|MDLZ66.05+1.11 (+1.70%) ▲|MDT98.69+2.15 (+2.23%) ▲|META612.09-2.90 (-0.47%) ▼|MMM179.35+5.01 (+2.87%) ▲|MO77.51-0.52 (-0.67%) ▼|MRK148.53-0.99 (-0.66%) ▼|MS186.52+2.22 (+1.20%) ▲|MSFT520.02-1.90 (-0.36%) ▼|MU852.74-32.00 (-3.62%) ▼|NEE84.99+1.28 (+1.52%) ▲|NFLX62.60+0.52 (+0.84%) ▲|NKE39.53+0.86 (+2.22%) ▲|NOW108.78+3.66 (+3.48%) ▲|NVDA206.58+1.94 (+0.95%) ▲|ORCL122.29-8.38 (-6.41%) ▼|PEP140.01+2.67 (+1.94%) ▲|PFE30.71+0.19 (+0.61%) ▲|PG163.79+2.22 (+1.37%) ▲|PLTR184.31+0.20 (+0.11%) ▲|PM208.04-0.75 (-0.36%) ▼|QCOM166.20+1.41 (+0.86%) ▲|RTX201.84+2.04 (+1.02%) ▲|SBUX103.86+0.21 (+0.20%) ▲|SCHW89.25+1.20 (+1.36%) ▲|SO94.31+0.60 (+0.64%) ▲|SPG222.83+5.08 (+2.33%) ▲|T21.44+0.03 (+0.14%) ▲|TMO685.44-11.56 (-1.66%) ▼|TMUS158.56+2.12 (+1.36%) ▲|TSLA408.55+8.74 (+2.18%) ▲|TXN308.30+7.46 (+2.48%) ▲|UBER67.19+1.94 (+2.97%) ▲|UNH397.41-9.57 (-2.35%) ▼|UNP307.49+3.49 (+1.15%) ▲|UPS109.57+1.32 (+1.22%) ▲|USB60.52+1.07 (+1.80%) ▲|V426.08+12.49 (+3.02%) ▲|VZ44.94+0.21 (+0.46%) ▲|WFC84.96+1.56 (+1.86%) ▲|WMT126.97+3.46 (+2.80%) ▲|XOM180.46-6.79 (-3.63%) ▼|
17 C
New York
Monday, November 2, 2026

Tag: program

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology...

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

Orbis International’s Flying Eye Hospital Arrives in Peru to Expand Access to Essential Eye Care

With support from Alcon, FedEx, and OMEGA, the Orbis Flying Eye Hospital returns to Peru to carry out a training project in the city of Arequipa.AREQUIPA,...

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

HorseWood & HorseBoost [Exclusive Report 2026] The Horse Gelatin Trick Male Enhancement Or Why Talking About Natural Vitality Supplement Horse Boost?

Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence.
Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence.

Ruvi AI (RUVI) Announces Phase 3 Has Reached 90% Sellout as Investors Race to Secure Remaining Tokens at $0.02

DUBAI, United Arab Emirates, June 14, 2026 (GLOBE NEWSWIRE) -- Ruvi AI, the AI-powered blockchain ecosystem combining artificial intelligence, decentralized infrastructure, creator monetization, and tokenized participation, has announced that Phase 3 of its ongoing token presale has now reached 90% completion.

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

Defiance ETFs Umumkan Penggantungan Sementara Dagangan Defiance Daily 2X Space ETF (SPCL) di Cboe BZX Exchange, Inc.

MIAMI, June 14, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs, peneraju dalam dana dagangan bursa bertema dan berleveraj, hari ini mengumumkan bahawa dagangan saham Defiance Daily 2X Space ETF (Cboe BZX: SPCL) telah digantung buat sementara waktu oleh Cboe BZX Exchange, Inc. (“Bursa”).

$100 No Deposit Bonus 200 Free Spins Real Money Casinos – All iGaming Experts Report Rising Demand for Free Spins Casinos

Vancouver, Canada, June 14, 2026 (GLOBE NEWSWIRE) --

$100 no deposit bonus 200 free spins real money promotions remain widely discussed as players look for practical ways to evaluate free spins casinos before making a deposit. As 50 no deposit free spins for real money bonus continue attracting players, many users are taking a closer look at promotional details and the overall value offered by no deposit bonus casinos.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProgram